Analysts have been eager to weigh in on the Healthcare sector with new ratings on Savara (SVRA) and BioNano Genomics (BNGO).
Savara (SVRA)
In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Hold rating on Savara. The company’s shares closed last Thursday at $1.51.
According to TipRanks.com, Higgins is a 4-star analyst with an average return of 10.2% and a 33.1% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Eiger Biopharmaceuticals, and Zynerba Pharmaceuticals.
Currently, the analyst consensus on Savara is a Strong Buy with an average price target of $3.33.
See today’s analyst top recommended stocks >>
BioNano Genomics (BNGO)
Oppenheimer analyst Kevin DeGeeter assigned a Buy rating to BioNano Genomics today and set a price target of $14.00. The company’s shares closed last Thursday at $4.41.
According to TipRanks.com, DeGeeter is a 5-star analyst with an average return of 36.7% and a 45.3% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Cyclacel Pharmaceuticals, Rocket Pharmaceuticals, and Sensei Biotherapeutics.
Currently, the analyst consensus on BioNano Genomics is a Strong Buy with an average price target of $13.58.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BNGO:
